Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,395,356
  • Shares Outstanding, K 61,569
  • Annual Sales, $ 2,252 M
  • Annual Income, $ 833,040 K
  • EBIT $ 789 M
  • EBITDA $ 807 M
  • 60-Month Beta 0.37
  • Price/Sales 25.20
  • Price/Cash Flow 310.32
  • Price/Book 9.25

Options Overview Details

View History
  • Implied Volatility 33.02% (+0.40%)
  • Historical Volatility 19.16%
  • IV Percentile 38%
  • IV Rank 32.08%
  • IV High 47.99% on 04/08/25
  • IV Low 25.95% on 01/22/25
  • Expected Move (DTE 14) 40.44 (4.49%)
  • Put/Call Vol Ratio 4.25
  • Today's Volume 887
  • Volume Avg (30-Day) 314
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 12,381
  • Open Int (30-Day) 12,822
  • Expected Range 860.73 to 941.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 5.91
  • Number of Estimates 10
  • High Estimate 7.36
  • Low Estimate 4.58
  • Prior Year 1.58
  • Growth Rate Est. (year over year) +274.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
831.26 +8.41%
on 11/06/25
934.62 -3.58%
on 12/03/25
+68.82 (+8.27%)
since 11/05/25
3-Month
698.92 +28.94%
on 09/25/25
934.62 -3.58%
on 12/03/25
+150.39 (+20.03%)
since 09/05/25
52-Week
510.05 +76.68%
on 06/30/25
934.62 -3.58%
on 12/03/25
+275.05 (+43.93%)
since 12/05/24

Most Recent Stories

More News
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

TORONTO , Nov. 5, 2025 /CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...

ARGX : 901.17 (-1.62%)
Analysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT), Argenx Se (ARGX) and AnaptysBio (ANAB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Microbot Medical (MBOT – Research Report), Argenx Se (ARGX – Research Report) and AnaptysBio (ANAB –...

ANAB : 44.35 (+2.42%)
ARGX : 901.17 (-1.62%)
MBOT : 2.37 (-3.66%)
Argenx SE Showcases Immunology Innovations at 2025 AANEM Meeting

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

ARGX : 901.17 (-1.62%)
TD Cowen Remains a Buy on Argenx Se (ARGX)

In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on Argenx Se, with a price target of $800.00. The company’s shares closed yesterday at $812.95.Elevate Your Investing Strategy:...

ARGX : 901.17 (-1.62%)
Argenx Se (ARGX) Gets a Buy from Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Argenx Se yesterday and set a price target of $775.00. The company’s shares closed yesterday at $799.56.Elevate Your Investing Strategy:...

ARGX : 901.17 (-1.62%)
RBC Capital Remains a Buy on Argenx Se (ARGX)

In a report released on October 8, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se. The company’s shares closed yesterday at $804.90.Elevate Your Investing Strategy: Take advantage of...

ARGX : 901.17 (-1.62%)
Argenx SE Calls Extraordinary Shareholder Meeting for November 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Argenx Se...

ARGX : 901.17 (-1.62%)
Goldman Sachs Sticks to Its Buy Rating for Argenx Se (ARGX)

Goldman Sachs analyst maintained a Buy rating on Argenx Se today and set a price target of $916.00. The company’s shares closed yesterday at $767.33.Elevate Your Investing Strategy: Take advantage of...

ARGX : 901.17 (-1.62%)
3 Healthcare Pathbreakers With Long-Term Tailwinds

These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.

ICLR : 185.87 (+0.05%)
EW : 86.19 (+0.48%)
ARGX : 901.17 (-1.62%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised...

ARGX : 901.17 (-1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

See More

Key Turning Points

3rd Resistance Point 941.00
2nd Resistance Point 929.00
1st Resistance Point 915.08
Last Price 901.17
1st Support Level 889.17
2nd Support Level 877.17
3rd Support Level 863.26

See More

52-Week High 934.62
Last Price 901.17
Fibonacci 61.8% 772.44
Fibonacci 50% 722.34
Fibonacci 38.2% 672.24
52-Week Low 510.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar